Sovaldi hepatitis C drug rakes in $5.8 billion for Gilead Gilead is being criticized for the steep price of Sovaldi. Will it lower the cost or continue to rake in billions of dollars in expense of Hepatitis C patients who cannot afford it? by Anne Francis